Cargando…
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical t...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184359/ https://www.ncbi.nlm.nih.gov/pubmed/32363212 http://dx.doi.org/10.1093/ofid/ofaa130 |
_version_ | 1783526592237010944 |
---|---|
author | Pastick, Katelyn A Okafor, Elizabeth C Wang, Fan Lofgren, Sarah M Skipper, Caleb P Nicol, Melanie R Pullen, Matthew F Rajasingham, Radha McDonald, Emily G Lee, Todd C Schwartz, Ilan S Kelly, Lauren E Lother, Sylvain A Mitjà, Oriol Letang, Emili Abassi, Mahsa Boulware, David R |
author_facet | Pastick, Katelyn A Okafor, Elizabeth C Wang, Fan Lofgren, Sarah M Skipper, Caleb P Nicol, Melanie R Pullen, Matthew F Rajasingham, Radha McDonald, Emily G Lee, Todd C Schwartz, Ilan S Kelly, Lauren E Lother, Sylvain A Mitjà, Oriol Letang, Emili Abassi, Mahsa Boulware, David R |
author_sort | Pastick, Katelyn A |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines. |
format | Online Article Text |
id | pubmed-7184359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-71843592020-04-29 Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) Pastick, Katelyn A Okafor, Elizabeth C Wang, Fan Lofgren, Sarah M Skipper, Caleb P Nicol, Melanie R Pullen, Matthew F Rajasingham, Radha McDonald, Emily G Lee, Todd C Schwartz, Ilan S Kelly, Lauren E Lother, Sylvain A Mitjà, Oriol Letang, Emili Abassi, Mahsa Boulware, David R Open Forum Infect Dis Review Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines. Oxford University Press 2020-04-15 /pmc/articles/PMC7184359/ /pubmed/32363212 http://dx.doi.org/10.1093/ofid/ofaa130 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Article Pastick, Katelyn A Okafor, Elizabeth C Wang, Fan Lofgren, Sarah M Skipper, Caleb P Nicol, Melanie R Pullen, Matthew F Rajasingham, Radha McDonald, Emily G Lee, Todd C Schwartz, Ilan S Kelly, Lauren E Lother, Sylvain A Mitjà, Oriol Letang, Emili Abassi, Mahsa Boulware, David R Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |
title | Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |
title_full | Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |
title_fullStr | Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |
title_full_unstemmed | Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |
title_short | Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |
title_sort | review: hydroxychloroquine and chloroquine for treatment of sars-cov-2 (covid-19) |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184359/ https://www.ncbi.nlm.nih.gov/pubmed/32363212 http://dx.doi.org/10.1093/ofid/ofaa130 |
work_keys_str_mv | AT pastickkatelyna reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT okaforelizabethc reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT wangfan reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT lofgrensarahm reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT skippercalebp reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT nicolmelanier reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT pullenmatthewf reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT rajasinghamradha reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT mcdonaldemilyg reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT leetoddc reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT schwartzilans reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT kellylaurene reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT lothersylvaina reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT mitjaoriol reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT letangemili reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT abassimahsa reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 AT boulwaredavidr reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19 |